Prometheus Biosciences EBIT

The latest EBIT for RXDX is $-160M as of March 2023. That compares with $-110M in the prior-year period — down 50.5% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Prometheus Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, RXDX's EBIT moved from $-110M to $-160M — a 50.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Prometheus Biosciences's operating scale or balance-sheet position.

Against Healthcare companies, RXDX currently prints $-160M for EBIT, while the sector average sits near $23B. That is roughly 100.7% below the sector mean. Large gaps often invite a closer look at Prometheus Biosciences's growth, margins, and balance sheet.

A EBIT figure of $-160M for RXDX is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting RXDX's EBIT ($-160M), review year-over-year change from $-110M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.